Emerald Advisers’s Dianthus Therapeutics DNTH Stock Holding History

Emerald Advisers’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.2M	Buy	+247,805	New	+$21.6M	0.57%	82

Other funds holding DNTH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Emerald Advisers's DNTH Position: Q2 2026 in Review

Emerald Advisers opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 247,805 shares worth $24.2M. The stake represents 0.57% of the portfolio and ranks #82 among its holdings.

75 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Emerald Advisers held 247,805 shares of Dianthus Therapeutics worth $24.2M as of Q2 2026.
Dianthus Therapeutics was a new Emerald Advisers position in Q2 2026.
Dianthus Therapeutics made up 0.57% of Emerald Advisers's portfolio in Q2 2026, its #82 holding.
75 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Emerald Advisers's 13F filing for Q2 2026, filed 5 Aug 2026.